Innovent Biologics, Inc. (HKG:1801)
85.50
+6.10 (7.68%)
At close: Mar 27, 2026
Innovent Biologics Market Cap
Innovent Biologics has a market cap or net worth of 148.36 billion as of March 27, 2026. Its market cap has increased by 124.44% in one year.
Market Cap
148.36B
Enterprise Value
131.20B
Revenue
14.51B
Ranking
n/a
PE Ratio
163.47
Stock Price
85.50
Market Cap Chart
Since October 31, 2018, Innovent Biologics's market cap has increased from 18.54B to 148.36B, an increase of 700.25%. That is a compound annual growth rate of 32.41%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 27, 2026 | 148.36B | 12.17% |
| Dec 31, 2025 | 132.27B | 120.60% |
| Dec 31, 2024 | 59.96B | -13.32% |
| Dec 29, 2023 | 69.17B | 34.57% |
| Dec 30, 2022 | 51.40B | -27.14% |
| Dec 31, 2021 | 70.55B | -38.71% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Oct 31, 2018 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| BeOne Medicines AG | 240.33B |
| WuXi Biologics | 133.89B |
| Akeso | 116.43B |
| Sino Biopharmaceutical | 105.33B |
| Sichuan Kelun-Biotech Biopharmaceutical | 99.66B |
| RemeGen | 68.68B |
| 3SBio | 59.89B |
| Biocytogen Pharmaceuticals (Beijing) | 41.27B |